Immunological characterization of factor VIII inhibitors by a sensitive micro-ELISA method

Thrombosis Research
J M Sánchez-CuencaJ A Aznar

Abstract

A micro-ELISA method for the immunological characterization of factor VIII (F. VIII) inhibitors is described. Microplates sensitized with purified monospecific anti-von Willebrand factor (vWF) IgG were firstly incubated with a commercial F. VIII concentrate and then with the samples containing the F. VIII inhibitors to be characterized. Peroxidase conjugated monospecific antisera were used to determine the Ig class and the light chain type. Alkaline phosphatase conjugated monoclonal antibodies were employed to investigate the IgG subclasses. The F. VIII inhibitors from 8 hemophiliacs and 1 patient with systemic lupus erythematosus (SLE) were characterized. All of them belonged to the IgG class but one case simultaneously exhibited another inhibitor of the IgA class. Eight inhibitors analyzed for light chains resulted to be polyclonal. In 7 cases the inhibitors belonged solely to the IgG4 subclass while in the other 2 cases contained all the 4 IgG subclasses. The method appears to be simple, accurate and highly sensitive (detecting as low as 0.156 Bethesda Units/ml) for the immunological characterization of F. VIII inhibitors.

Citations

May 15, 2013·PloS One·Kenneth B LewisUNKNOWN PATH (Personalized Alternative Therapies for Haemophilia) Study Investigators
May 15, 2007·Haemophilia : the Official Journal of the World Federation of Hemophilia·M A SahudA R Thompson
Jun 15, 2017·International Journal of Laboratory Hematology·M B IrigoyenN V Galassi
Apr 23, 2002·Haemophilia : the Official Journal of the World Federation of Hemophilia·S Lacroix-DesmazesM D Kazatchkine
Feb 12, 1998·Scandinavian Journal of Clinical and Laboratory Investigation·O Takamiya, S Kinoshita

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.